血清乳酸脱氢酶（LDH）作为非霍奇金淋巴瘤的预后指标。

Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma.

作者信息

Endrizzi L, Fiorentino M V, Salvagno L, Segati R, Pappagallo G L, Fosser V

出版信息

Eur J Cancer Clin Oncol. 1982 Oct;18(10):945-9. doi: 10.1016/0277-5379(82)90242-5.

Abstract

According to pretreatment values of serum lactate dehydrogenase (LDH), 113 consecutive patients with non-Hodgkin's lymphoma were divided into three levels: level 1 (within normal range) with LDH less than 250 U/l; level 2 (moderately increased) with LDH between 250 and 500 U/l; level 3 (highly increased) with LDH more than 500 U/l. LDH was elevated in 46 of 113 patients (41%). Normal values of LDH were associated with a better response to therapy and a longer survival, independent of histological type and clinical stage, with one exception; in stage IV patients conclusions could not be drawn concerning the response to therapy (complete remission occurred only in 8 of 44). Even though level 2 patients behaved slightly better than level 3 patients, no statistical difference has been observed between the two levels. Accordingly, serum LDH can be considered a useful predictor of response to therapy and of survival in non-Hodgkin's lymphoma.

摘要

根据血清乳酸脱氢酶（LDH）的预处理值，113例连续的非霍奇金淋巴瘤患者被分为三个水平：1级（正常范围），LDH低于250 U/l；2级（中度升高），LDH在250至500 U/l之间；3级（高度升高），LDH高于500 U/l。113例患者中有46例（41%）的LDH升高。LDH正常与对治疗的更好反应和更长生存期相关，与组织学类型和临床分期无关，但有一个例外；在IV期患者中，无法得出关于治疗反应的结论（44例中仅有8例完全缓解）。尽管2级患者的表现略优于3级患者，但两级之间未观察到统计学差异。因此，血清LDH可被视为非霍奇金淋巴瘤治疗反应和生存的有用预测指标。